New Whitepaper Explores How Malvern Instruments Extends a QbD Approach to Instrument Design
‘Extending the boundaries of QbD’, a new whitepaper from Malvern Instruments, explores the application of Quality by Design (QbD) principles to the development of analytical instrumentation and the benefits this brings for users. Taking the example of Malvern’s development of the Mastersizer 3000 particle size analyser, the authors illustrate how instrument companies are aligning with the QbD philosophy. This offers pharmaceutical customers the reassurance of closely similar working practices and products that meet exacting customer standards.
The central idea of QbD is that quality should be built into a product from the outset. It is an approach based on the development of a thorough understanding of the variables that affect performance, quantification of the risks associated with those impacts, and knowledge-based risk mitigation. Taking a similar risk assessment-based QbD approach to instrument design builds consistency and performance into a product from the outset. This thought and knowledge translates directly into an analytical tool that is not only reliable and compliant with regulatory requirements but is also efficient, productive and easy to use.
The starting point for QbD is the clear definition of a target performance profile for the product. The design of the Mastersizer 3000 began with a rigorous assessment of industrial requirements for particle size analysis and, since the product is wrapped by a cycle of continuous improvement, that assessment continues today. The third anniversary of the instrument has been marked with the launch of two new products that deliver even smarter particle sizing. Hydro Sight is a state-of-the-art imaging accessory that makes it quicker and easier to develop and apply the robust particle sizing methods that are essential across industry, by delivering real-time visual monitoring of the dispersion process that precedes every laser diffraction particle size measurement. Hydro SV is a wet dispersion accessory that enables measurement with just a few milligrams of sample.
To download ‘Extending the boundaries of QbD’ from the Malvern website, click here.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance